{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:11:21Z","timestamp":1778134281433,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Efficacy of available treatments for liposarcoma (LPS), including dedifferentiated liposarcoma (DDLPS) is limited, and detailed real-world clinical data for patients with LPS treated in Japan are scarce. We used the MASTER KEY Registry Database to evaluate the clinical characteristics and outcomes of patients with advanced\/metastatic LPS treated with systemic antineoplastic therapy in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This non-interventional\/observational cohort study included patients with LPS, including DDLPS, and well-differentiated LPS (WDLPS), and a history of systemic antineoplastic therapy, enrolled in the MASTER KEY Project Registry Database from 1 May 2017 to 31 December 2022. Outcomes were analysed by type of treatment. Primary outcomes: progression-free survival (PFS); overall survival (OS). Secondary outcomes: overall response rate; disease control rate. Sensitivity analyses (prospective registry subgroup) were performed to minimize immortal time bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Since 2017, 100 patients with LPS were prospectively enrolled in the database; of these, 62 had DDLPS and 11 had WDLPS. In patients with LPS, median PFS was 11.1\u00a0months after first-line (1\u00a0L) pharmacotherapy and 6.9\u00a0months after 1\u00a0L doxorubicin. In patients with DDLPS, median PFS was 6.9\u00a0months after 1\u00a0L pharmacotherapy and 4.4\u00a0months after 1\u00a0L doxorubicin. Median OS after 1\u00a0L pharmacotherapy was 45.8\u00a0months in patients with LPS, and 40.7\u00a0months in those with DDLPS. Median OS in the sensitivity analysis was not reached for patients with LPS and was 13.9\u00a0months for the DDLPS subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data investigating DDLPS in Japanese patients highlight the poor outcomes and lack of effective treatment options in the real-world clinical practice setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag004","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:43:41Z","timestamp":1769777021000},"page":"577-586","source":"Crossref","is-referenced-by-count":0,"title":["Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-7361","authenticated-orcid":false,"given":"Hitomi Sumiyoshi","family":"Okuma","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital , 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, Kyushu University , 3-1-1 Maidashi, Fukuoka, 812-8582 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital , 1-1 Seiryo-machi, Aoba-ku, Sendai-shi, Miyagi, 980-8574 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Division of Clinical Cancer Genomics, Hokkaido University Hospital , North14, West 5, Kita-ku, Sapporo 060-8648 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-8203","authenticated-orcid":false,"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital , 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Kamikura","sequence":"additional","affiliation":[{"name":"Clinical Research Support Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Sadachi","sequence":"additional","affiliation":[{"name":"Clinical Research Support Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[{"name":"Clinical Research Support Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ichimura","sequence":"additional","affiliation":[{"name":"Clinical Research Support Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Real World Evidence Japan, Nippon Boehringer Ingelheim Co., Ltd , 2-1-1 Osaki, Shinagawa-ku, Tokyo, 141-6017 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Boehringer Ingelheim Co., Ltd , 2-1-1 Osaki, Shinagawa-ku, Tokyo, 141-6017 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3534-8296","authenticated-orcid":false,"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of International Clinical Development, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[{"name":"Department of International Clinical Development, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2026050701221631800_ref1","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.2147\/OTT.S112580","article-title":"Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas","volume":"9","author":"De Vita","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2026050701221631800_ref2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/JCO.2017.74.9598","article-title":"Clinical and molecular spectrum of liposarcoma","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026050701221631800_ref3","doi-asserted-by":"publisher","first-page":"e20294","DOI":"10.1371\/journal.pone.0020294","article-title":"Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing","volume":"6","author":"Ducimetiere","year":"2011","journal-title":"PLoS One"},{"key":"2026050701221631800_ref4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2147\/OTT.S127955","article-title":"Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas","volume":"10","author":"Recine","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2026050701221631800_ref5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000527632","article-title":"Eribulin in patients with liposarcoma and leiomyosarcoma: a retrospective single-center experience","volume":"101","author":"Steinbrecher","year":"2023","journal-title":"Oncology"},{"key":"2026050701221631800_ref6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/13543784.2019.1607291","article-title":"Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"28","author":"Chamberlain","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"2026050701221631800_ref7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jos.2017.03.017","article-title":"Statistics of soft-tissue sarcoma in Japan: report from the bone and soft tissue tumor registry in Japan","volume":"22","author":"Ogura","year":"2017","journal-title":"J Orthop Sci"},{"key":"2026050701221631800_ref8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/jjco\/hyae088","article-title":"Soft-tissue sarcoma in Japan: National Cancer Registry-based analysis from 2016 to 2019","volume":"54","author":"Ogura","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026050701221631800_ref9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/cpt.1453","article-title":"Have we found the key to unravel treatment development lags for rare cancers?: MASTER KEY project","volume":"106","author":"Okuma","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026050701221631800_ref10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/cpt.1817","article-title":"MASTER KEY project: powering clinical development for rare cancers through a platform trial","volume":"108","author":"Okuma","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026050701221631800_ref11","doi-asserted-by":"publisher","first-page":"S479","DOI":"10.1016\/j.jcot.2020.04.013","article-title":"Epidemiology and survival of liposarcoma and its subtypes: a dual database analysis","volume":"11","author":"Amer","year":"2020","journal-title":"J Clin Orthop Trauma"},{"key":"2026050701221631800_ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194578","article-title":"The immune contexture of liposarcoma and its clinical implications","volume":"14","author":"Resag","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026050701221631800_ref13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1159\/000524939","article-title":"Established and experimental systemic treatment options for advanced liposarcoma","volume":"45","author":"Sch\u00f6ffski","year":"2022","journal-title":"Oncol Res Treat"},{"key":"2026050701221631800_ref14","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdr485","article-title":"Advanced well-differentiated\/dedifferentiated liposarcomas: role of chemotherapy and survival","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann Oncol"},{"key":"2026050701221631800_ref15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","article-title":"Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study","volume":"15","author":"Savina","year":"2017","journal-title":"BMC Med"},{"key":"2026050701221631800_ref16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data","volume":"49","author":"Maringe","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2026050701221631800_ref17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2026050701221631800_ref18","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1016\/j.ejca.2005.07.023","article-title":"Differential sensitivity of liposarcoma subtypes to chemotherapy","volume":"41","author":"Jones","year":"2005","journal-title":"Eur J Cancer"},{"key":"2026050701221631800_ref19","doi-asserted-by":"publisher","first-page":"777872","DOI":"10.3389\/fphar.2022.777872","article-title":"The role of trabectedin in soft tissue sarcoma","volume":"13","author":"Nakamura","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026050701221631800_ref20","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.Ccr-22-2092","article-title":"A single-arm phase Ib\/II study of lenvatinib plus eribulin in advanced liposarcoma and leiomyosarcoma","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/577\/66747332\/hyag004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/577\/66747332\/hyag004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:22:24Z","timestamp":1778131344000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/5\/577\/8459412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,4]]},"published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag004","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,4]]}}}